6; p=0.01), development of acute kidney injury during hospitalization (hazard ratio=23.2; p=0.01) and baseline selleck kinase inhibitor mean arterial pressure (hazard ratio= 0.92; p=0.01) were found to be independent significant predictors of 90-day transplant free mortality. The incidence of global adverse events (73.3 vs 81.3%; p= 0.68) and drug related adverse events (20.0 vs 25.0; p= 1.0) were similar between the two groups. Conclusions: The combination of meropenem plus daptomycin is more effective than ceftazidime in

the treatment of hospital acquired SBP. The effectiveness of the first line treatment is associated with improved 90 day survival in these patients. ClinicalTrials. gov Identifier: NCT01455246

Disclosures: Umberto Cillo – Grant/Research Support: Novartis, Bayer, Astellas Paolo Angeli – Advisory Committees or Review Panels: Sequana Medical The following people have nothing to disclose: Salvatore Piano, Freddy Salinas, Filippo Morando, Marta Cavallin, Antonietta Romano, Silvia Rosi, Marialuisa Stanco, Silvano Fasolato, Antonietta Sticca, Marco Senzolo, Patrizia Burra, Enrico Gringeri, Angelo Gatta Background: The incidence, characteristics and prognostic significance of bacterial Erlotinib manufacturer infections (BI) occurring in the course of compensated viral cirrhosis are unknown. The aim of the CirVir cohort was to assess the incidence and predictive factors of complications

in HBV- or HCV-related compensated cirrhosis. Methods: This study involved 35 French centres. Inclusion criteria were histologically proven HCV- or HBV-related cirrhosis, Child-Pugh A, no previous hepatic complication including HCC. Patients were prospectively screened for HCC. Results: A total of 1672 patients were consecutively enrolled from March 2006 to June 2012 [mean age 54.9 yrs, males 67.3%; HCV 1323, HBV 318, HCV-HBV co-infection 31]. During a median follow-up of 43 months, 219 BI occurred in 180 patients (5-yr cumulative incidence, cumI: 13.6%). Among them, 187 (94.4%) were symptomatic, 19 of which occurred as a septic shock (8.7%). Main sites of BI were lung (66, 30.6%), urine (55, 25.5%), skin (24, 11.1%), and peritoneum (SBP) medchemexpress (21, 9.7%) [50 others (23.1%), 3 missing data]. The risk of a first BI occurrence was higher in HCV than in HBV patients (5-year cumI: 15.8% vs 5.5%, Log-rank=0.0009). Among 159 HCV patients who developed BI, 50 (31.6%) were infected while treated with an interferon-based regimen. HCV patients who developed a first BI had a higher probability of subsequent hepatic decompensation (5-yr cumI: 49.3% vs 11.7%, Log- rank<0.0001) and death (5-yr cumI: 48.3% vs 8.3%, Log- rank<0.0001). In HBV patients, an episode of BI only impaired survival (5-yr cumI: 34.8% vs 1.9%, Log-rank<0.0001).